Ammon

FNB Delivers More Than $7 Million for Hill District in Pittsburgh

Retrieved on: 
Wednesday, September 22, 2021
Midcap, Ammon, F.N.B. Corporation, Insurance, Partnership, New, Music, Pittsburgh Penguins Foundation, Solution, Piedmont Triad, First National Bank, Overalls, Investment, Centre Avenue, Workforce, Digital divide, Student, Multimedia, S&P Global Ratings, Urban Redevelopment Authority, Centre Avenue YMCA Building, Global Industry Classification Standard, Pittsburgh Penguins, Company, Rehabilitation, Standard, GICS, Housing, Community development, Parcel, Small business, High Point, Creativity, Barbershop, Winston-Salem, North Carolina, Economic development, Organization, FNB, District, NYSE, Government, Community development financial institution, Renewable energy, Bank, Financial services, Real estate, Tunnel

Corporation (NYSE: FNB) announced it has delivered an initial payment of nearly $7.2 million to the Greater Hill District Reinvestment Fund to support community investment and development.

Key Points: 
  • Corporation (NYSE: FNB) announced it has delivered an initial payment of nearly $7.2 million to the Greater Hill District Reinvestment Fund to support community investment and development.
  • With a long history of service to the community, FNB's total investment in the Hill District is in excess of $200 million in loans, investments and grants.
  • The Company will continue to deepen its support in the Hill District and Pittsburgh region overall as the FNB Financial Center development progresses, with completion anticipated in 2023.
  • Corporation (NYSE: FNB), headquartered in Pittsburgh, Pennsylvania, is a diversified financial services company operating in seven states and the District of Columbia.

Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions

Retrieved on: 
Wednesday, April 15, 2020
Biotechnology, Hospitals, Pharmaceutical, Health, Biotechnology, Ammon, Geography of Jordan, Gilead, Moab, Tourism in Jordan, Life sciences, Bible

In light of this change, stockholders will not be able to attend the Annual Meeting in person.

Key Points: 
  • In light of this change, stockholders will not be able to attend the Annual Meeting in person.
  • The Annual Meeting will be held Wednesday, May 6, 2020 at 10:00 a.m. Pacific Daylight Time, as previously scheduled.
  • As described in the proxy materials for the Annual Meeting, holders of our common stock at the close of business on March 13, 2020, the record date, are entitled to participate in the Annual Meeting.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14

Retrieved on: 
Monday, May 6, 2019
Health, Biotechnology, Clinical trials, Hospitals, Pharmaceutical, Biotechnology, Ammon, Geography of Jordan, Gilead, Moab, Tourism in Jordan, Life sciences, Bible

The audio portion of the fireside chat will be accessible live through the companys Investors page at http://investors.gilead.com/ .

Key Points: 
  • The audio portion of the fireside chat will be accessible live through the companys Investors page at http://investors.gilead.com/ .
  • Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
  • The company strives to transform and simplify care for people with life-threatening illnesses around the world.
  • For more information on Gilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

Retrieved on: 
Tuesday, April 16, 2019
Health, Biotechnology, Genetics, Hospitals, Pharmaceutical, Research, Science, Biotechnology, Gilead Sciences, Ammon, Life sciences, Gilead, Bible

Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.

Key Points: 
  • Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.
  • We are excited about the opportunity to partner with insitro to tackle the scientific challenges associated with this complex disease.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
  • For more information on Gilead Sciences, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

CPSI Appoints Jeffrey A. Strong to Board of Directors

Retrieved on: 
Wednesday, February 27, 2019
Technology, Software, Other Technology, Practice Management, Health, Hospitals, Managed care, Ammon, Geography of Jordan, Gilead, Moab, Tourism in Jordan, Board of directors, Business, Bible, Articles

CPSI (NASDAQ: CPSI) (CPSI or the Company), a community healthcare solutions company, today announced that the Company has elected Jeffrey A.

Key Points: 
  • CPSI (NASDAQ: CPSI) (CPSI or the Company), a community healthcare solutions company, today announced that the Company has elected Jeffrey A.
  • Strong, Managing Partner of Gilead Capital LP, as a Class I director of the Board of Directors (the Board), filling the vacancy resulting from John C. Johnsons resignation from the Board in November 2018.
  • CPSI will also further refresh the Board with a new independent director, who is mutually agreeable with Gilead, before the Companys 2020 Annual Meeting of Stockholders.
  • Mr. Strong added, Gilead appreciates the constructive dialogue we have had with the Board and management about CPSIs strategy and unique customer value proposition.

Hilliard Martinez Gonzales LLP: Gilead Sued For Intentionally Withholding Safer HIV Drug

Retrieved on: 
Saturday, November 17, 2018
Hepatotoxins, Ammon, Geography of Jordan, Gilead, Moab, Tourism in Jordan, Management of HIV/AIDS, TAF, Health, Pharmaceutical industry, Bible

CORPUS CHRISTI, Texas, Nov. 17, 2018 /PRNewswire/ --Today Bob Hilliard filed a lawsuit against Gilead, claiming the giant drug company intentionally kept a safer HIV drug from hundreds of thousands of patients so as to protect its multi-billion dollar patent on a less safe drug.

Key Points: 
  • CORPUS CHRISTI, Texas, Nov. 17, 2018 /PRNewswire/ --Today Bob Hilliard filed a lawsuit against Gilead, claiming the giant drug company intentionally kept a safer HIV drug from hundreds of thousands of patients so as to protect its multi-billion dollar patent on a less safe drug.
  • Today, after withholding TAF for an entire decade and during which time Gilead madesevenpatent applications for TAF products it had purportedly abandoned, Gilead openly markets TAF as a safer alternative to TDF.
  • We believe the evidence will show that Gilead withheld the equally effective but safer medication for one primary reasonbillions in profits.
  • Hilliard Martinez Gonzales LLP (HMG) has been successfully representing clients in the United States and Mexico since 1986.